Ultragenyx Pharmaceutical(US:RARE) TMX Newsfile·2026-03-26 13:35Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about the efficacy of its drug setrusumab in treating Osteogenesis Imperfecta [2][5]. Company Overview - Ultragenyx Pharmaceutical Inc is a biopharmaceutical company listed on NASDAQ under the ticker RARE, focusing on developing innovative therapies for rare diseases [2]. Legal Proceedings - A federal securities class action has been filed against Ultragenyx, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Ultragenyx and its executives misrepresented the reliability of data from the Phase III Orbit study, leading to a false impression of the drug's effectiveness [5]. Study Results and Stock Impact - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, resulting in a stock price drop of over 25% [6]. - On December 29, 2025, the company announced that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, causing a further decline in stock price of more than 42% [7][8]. Investor Actions - Investors who suffered losses during the period from August 3, 2023, to December 26, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][2].